Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
New Pathology is an independent molecular pathology and precision oncology consulting service for professional stakeholders, with a focus on molecular pathology, oncology biomarkers, genomic diagnostics, reimbursement strategy, and market access. The website clearly states that it does not provide diagnostic services for public-facing patients; instead, it serves pharmaceutical companies, biotech firms, diagnostic developers, investors, market research organizations, and selected laboratory or clinical strategy projects.
Its core value lies not in SaaS software functionality, but in highly specialized medical and diagnostic strategy consulting. Services include strategic planning for oncology biomarkers from discovery through clinical implementation; evaluation of technical approaches such as NGS panels, WGS/WES, liquid biopsy, ctDNA, and MRD in solid tumors; and positioning of biomarkers such as PD-L1, HER2, TMB, HRD, ESR1, and MTAP in clinical and reimbursement contexts. Another key focus is reimbursement and market access for molecular diagnostics in Germany and Europe, including EBM, GOÄ, selective contracts, clinical utility, and the impact of health economics evidence on reimbursement decisions.
The website does not disclose packages, pricing, project timelines, or delivery templates, so pricing is likely customized by consulting project or expert interview. There is also no information commonly found with enterprise software, such as free trials, subscription tiers, online platforms, APIs, integrations, or permission management. As a result, when evaluated from a SaaS perspective, the level of productization appears low.
Its strengths are a very clear positioning, with a focus on precision oncology diagnostics, molecular pathology, and market access, while also spanning research, clinical development, routine care, and reimbursement implementation. It supports English, German, and Dutch, making it suitable for cross-European projects. Its shortcomings are that the website mainly presents service descriptions and lacks customer cases, compliance and security details, service workflows, SLAs, and price transparency. It is not a good fit for teams looking to purchase a standardized software tool.
It is better suited for pharmaceutical diagnostic departments, companion diagnostic developers, investment firms, market research teams, and organizations seeking to understand the molecular diagnostics reimbursement landscape in Germany or Europe. The review text does not provide information about access from China, so actual connectivity is unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on newpathology.de official site.
newpathology.de is an Germany SaaS provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach newpathology.de directly.